Skip to main content
Figure 5 | Arthritis Res Ther

Figure 5

From: Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

Figure 5

Link between changes in IL-6 and osteoprotegerin (OPG) production by rheumatoid arthritis (RA) synoviocytes and clinical response. Changes, expressed as ΔIL-6 and ΔOPG production by RA synoviocytes before and 4 hours after the first infliximab infusion, are separated according to the American College of Rheumatology (ACR) clinical response (good or poor) at 54 weeks (n = 20). A good clinical response was defined as an ACR 50 response or better (n = 12).

Back to article page